Paul Burgess Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Burgess TBIO stock SEC Form 4 insiders trading

Paul has made over 1 trades of the Telesis Bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 71,833 units of TBIO stock worth $2,729,654 on 14 September 2021.

The largest trade he's ever made was selling 71,833 units of Telesis Bio Inc stock on 14 September 2021 worth over $2,729,654. On average, Paul trades about 17,958 units every 0 days since 2019.

You can see the complete history of Mr. Burgess stock trades at the bottom of the page.

Paul Burgess biography

Paul Burgess J.D. serves as Chief Operating Officer, Chief Legal Officer of the Company. He has served as our chief legal officer since June 2018 and chief operating officer since December 2019. Prior to that, he served as our general counsel since May 2016. He previously served as our vice president of intellectual property from March 2015 until May 2016. Mr. Burgess was also vice president of intellectual property at Scholar Rock, Inc., a biotechnology company, from July 2015 to April 2016 and held the same position at BIND Therapeutics, a biotechnology company, from 2008 to July 2015. He was also head of intellectual property at Civitas Therapeutics, a biopharmaceutical company, from March 2011 to February 2015. Prior to becoming a lawyer, Mr. Burgess worked as a scientist at Genetics Institute from 1995 to 1999. He received a J.D. from Northeastern University, M.S. in pharmacology from Northeastern University and B.S. in biology from Merrimack College.

How old is Paul Burgess?

Paul Burgess is 46, he's been the Chief Operating Officer i Chief Legal Officer of Telesis Bio Inc since 2019. There are 11 older and 2 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.

What's Paul Burgess's mailing address?

Paul's mailing address filed with the SEC is C/O TRANSLATE BIO, INC., 29 HARTWELL AVE, LEXINGTON, MA, 02421.

Insiders trading at Telesis Bio Inc

Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk oraz Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.

What does Telesis Bio Inc do?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Complete history of Mr. Burgess stock trades at Telesis Bio Inc

Telesis Bio Inc executives and stock owners

Telesis Bio Inc executives and other stock owners filed with the SEC include:

• Ronald Renaud,
  President, Chief Executive Officer, Director
• Richard Wooster,
  Chief Scientific Officer
• John Schroer,
  Chief Financial Officer, Treasurer
• Brian Fenton,
  Chief Business Officer
• Robert Plenge,
  Independent Director
• Robert Meyer,
  Independent Director
• George Demetri,
  Independent Director
• Daniel Lynch,
  Independent Chairman of the Board
• Daniella Beckman,
  Independent Director
• Owen Hughes,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Ann Barbier,
  Chief Medical Officer
• Frank DeRosa,
  Chief Technology Officer
• Paula Cloghessy,
  Chief Human Resource Officer
• Paul Burgess,
  Chief Operating Officer, Chief Legal Officer
• Michael Heartlein,
  Founder, Executive Vice President
• Paul M Meister,
  Director
• Everett Rand Sutherland,
  President
• Brian M. Jr. Gallagher,
  Director
• Ventures Fund Llc Mrl,
  10% owner
• Venture Fund Viii, L.P.Atla...,
  
• Plc Gsk,
  10% owner
• Human Genetic Therapies, In...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• James B Weissman,
  
• Michael R. Hodges,
  
• Todd Krueger,
  
• Steven J Golub,
  
• Sarah E. Hlavinka,
  
• Daniel Glenn Gibson,
  Chief Technology Officer
• Human Genetic Therapies, In...,
  
• Group Llc/Ma Baupost Group ...,
  
• Brendan Smith,
  Chief Financial Officer
• Sanofi,
  10% owner
• Ventures Gp, Llc Northpond ...,
  
• Fund Iv, Llc Broad Oak,
  10% owner
• William Snider,
  Director
• William J Kullback,
  Chief Financial Officer
• Rob Cutler,
  Chief Legal Officer
• Todd Robert Nelson,
  Chief Executive Officer
• Eric Eugene Esser,
  President & CEO
• Frank Witney,
  
• Christine A Tsingos,
  
• Annette Tumolo,
  
• Gregory J. Herrema,
  
• Jami K Nachtsheim,